A single-dose, four-cycle, fully repetitive crossover bioequivalence of dabigatran etexilate in Chinese
The enrollment process in this study was finalized on the "Chemical Drug Bioequivalence Trial Record Information Platform." ( http://www.chinadrugtrials.org.cn , 04/07/2023, CTR20231968).
Authors
- Zhuan Yang
- Danfeng Yu
- Jiyu Chen (ORCID: https://orcid.org/0000-0002-7006-6430)
- Yan He (ORCID: https://orcid.org/0000-0003-4357-4082)
- Ying Wang (ORCID: https://orcid.org/0000-0002-9936-2663)
- Na Li (ORCID: https://orcid.org/0000-0002-0404-6431)
- Yan Zeng (ORCID: https://orcid.org/0000-0002-0925-7879)
- Lü Chen (ORCID: https://orcid.org/0000-0002-7512-1865)
- Qin Li (ORCID: https://orcid.org/0000-0002-2470-6089)
- Xiaojuan Zhang (ORCID: https://orcid.org/0000-0003-3578-6616)
- Peng Du (ORCID: https://orcid.org/0000-0002-3466-8020)
- Yan Zhou
- Chen Zeng (ORCID: https://orcid.org/0000-0001-5350-7639)
- Chen Cai (ORCID: https://orcid.org/0009-0006-6139-5490)
- Yun Xiong
- Shijing Liu (ORCID: https://orcid.org/0000-0002-9484-5543)
- Lin Liu (ORCID: https://orcid.org/0000-0002-8472-3067)
- Qian Zhang (ORCID: https://orcid.org/0000-0001-5975-9781)
Institutions
- Guiyang Medical University (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
Publication Details
- Journal
- BMC Pharmacology and Toxicology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1186/s40360-025-00896-1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00